Look around the room.
Then look down at your own waistline.
Then look at your patients.
For many clinicians, the most obvious biomarker of metabolic dysfunction is not hidden in an advanced lab panel. It is sitting right in front of us. Expanding abdominal girth is often the visible fingerprint of worsening insulin resistance, visceral adiposity, and the inflammatory cascade that drives cardiometabolic decline. Modern guidelines increasingly emphasize that adiposity—especially central adiposity—is not just a cosmetic issue. It is a biologic signal tied to progression toward prediabetes, type 2 diabetes, dyslipidemia, fatty liver disease, hypertension, vascular injury, and long-term chronic disease risk.[1-4]
In my view, insulin resistance is one of the most modifiable risk factors in medicine, yet it continues to be ignored until fasting glucose and A1c drift far enough to earn a diagnosis. By then, the process has been smoldering for years. Long before the presence of type 2 diabetes, hyperinsulinemia, visceral fat accumulation, oxidative stress, mitochondrial dysfunction, and low-grade inflammation reshaping physiology in the wrong direction.[1-4]
WHY THE WAISTLINE MATTERS
BMI has value, but it can miss what matters most metabolically. Central adiposity is a much more meaningful warning sign. Waist circumference and waist-to-height ratio track cardiometabolic risk because they reflect the burden of abdominal fat, especially visceral fat, which is metabolically active and strongly linked to insulin resistance.[2-4] A practical clinical message is simple: when the waistline keeps growing, chronic disease risk is often growing with it.
Visceral fat is not passive storage tissue. It behaves more like an endocrine organ. Specifically, it releases free fatty acids, inflammatory cytokines, and signaling molecules that impair insulin signaling in the liver and muscle. Further, it increases hepatic glucose output, worsens triglycerides levels, and promotes endothelial dysfunction.[3,4] This is precisely why a patient may “not eat that badly” by their own report, yet still move steadily toward metabolic syndrome. Their biology has already shifted.
INSULIN RESISTANCE IS NOT JUST ABOUT GLUCOSE
This is where many clinicians—and many patients—still get tripped up. Insulin resistance is not simply a blood sugar problem. It is a systems problem. Insulin resistance:
Pushes the pancreas to make more insulin.
Drives fat storage, especially around the abdomen.
Worsens triglycerides and small dense LDL patterns.
Fuels fatty liver.
Contributes to vascular dysfunction, and often goes hand-in-hand with rising blood pressure.
Increases oxidative stress and mitochondrial strain.
Lays the groundwork for type 2 diabetes, atherosclerotic disease, and declining metabolic resilience.[1,3-6]
This is why I believe clinicians should stop waiting for diabetes to “arrive.” We should be identifying the terrain earlier, which includes: elevated fasting insulin, high-normal fasting glucose, rising A1c, increased waist circumference, elevated triglycerides, low HDL, increasing ApoB, elevated liver enzymes, and signs of fatty liver. These are not random abnormalities. They are often different faces of the same metabolic fire.
FATTY LIVER: ONE OF THE CLEAREST EXPRESSIONS OF INSULIN RESISTANCE
One of the most important places that insulin resistance manifests is the liver. Current guidance recognizes metabolic dysfunction-associated steatotic liver disease (SLD) as intrinsically tied to obesity, insulin resistance, dyslipidemia, and cardiometabolic disease.[5,6] In plain English, the liver is often where metabolic overload becomes visible.
When insulin signaling is impaired, the liver continues to produce glucose when it should not, while simultaneously packaging and storing excess fat. Over time this can lead to hepatic steatosis, inflammation, and, in some patients, progressive injury.[5,6] This is why mild to moderate fatty liver is not a side issue. It is often a strong clue that the entire metabolic network is under strain.
WHAT CLINICIANS SHOULD BE THINKING ABOUT
If the waistline is expanding, don’t just think “weight.”
Think insulin.
Think liver.
Think mitochondria.
Think oxidative stress.
Think lipids.
Think vascular health.
Insulin resistance usually responds best when we address the process from multiple angles: food quality, refined carbohydrate burden, visceral adiposity, sleep, movement, oxidative stress, mitochondrial function, hepatic fat handling, membrane health, and nutrient repletion. This is where targeted nutritional intervention can become clinically meaningful.
CORE NUTRITIONAL INGREDIENTS FOR GLUCOSE-INSULIN SUPPORT*
Nutritional supplements and dietary intervention do not treat diseases, but address the underlying dysfunction, as reflected in the following research.
Berberine
Berberine has some of the best human evidence in the nutritional space for supporting healthy glucose metabolism and insulin sensitivity. Meta-analyses of randomized trials report improvements in fasting glucose, HbA1c, and broader metabolic markers in patients with type 2 diabetes and related metabolic dysfunction.[7,8] Mechanistically, it appears to support AMPK signaling, glucose uptake, and hepatic metabolic regulation.
Cinnamon extract
Cinnamon is not a magic bullet, but it remains a reasonable adjunct for supporting healthy glycemic regulation. Meta-analyses suggest benefits for fasting glucose and, in some datasets, lipid parameters, though trial heterogeneity remains an issue.[9,10] In clinical practice, this means cinnamon belongs in the conversation as part of a broader strategy, not as a stand-alone answer.
Chromium
Chromium remains relevant for patients with impaired glucose handling, particularly when the goal is to support normal insulin function and carbohydrate metabolism. Meta-analytic data suggests chromium supplementation can improve glycemic control markers in type 2 diabetes, though response variability exists.[11]
Mulberry leaf extract
Mulberry leaf extract is especially interesting for postprandial glucose control. Human trials show it can reduce the rise in post-meal glucose and insulin after carbohydrate exposure, making it a useful tool when the clinical picture includes glucose excursions, carbohydrate sensitivity, or both.[12,13]
This is why a formula such as Glucose-IR makes sense.*
WHY MITOCHONDRIA MATTER IN INSULIN RESISTANCE
Insulin resistance is not just a receptor problem. It is also an energy problem. Mitochondrial strain and oxidative stress are deeply woven into the physiology of poor insulin signaling and fatty liver. When the cell cannot efficiently process fuel, the result is often a buildup of lipid intermediates, inflammation, and redox imbalance. Over time, this worsens metabolic inflexibility.
R-alpha lipoic acid
Alpha-lipoic acid has supportive human evidence for improving glycemic and inflammatory markers. Meta-analyses suggest benefits in glucose homeostasis and insulin resistance indices in metabolically challenged populations.[14,15] It also plays a meaningful antioxidant and mitochondrial support role.
Acetyl-L-carnitine
Carnitine biology matters because fatty acid transport into mitochondria matters. Carnitine supplementation has shown supportive evidence in NAFLD-related outcomes, including liver enzymes, triglycerides, and HOMA-IR in meta-analytic data, although the total evidence base is still developing.[16,17] Acetyl-L-carnitine adds additional mitochondrial support relevance.
NAC
N-acetylcysteine (NAC) deserves attention because oxidative stress is not a side note in insulin resistance; it is part of the pathology. NAC supports glutathione status and redox balance. Human data in fatty liver are mixed but suggest potential benefit in some liver-related outcomes, while preclinical and mechanistic work strongly support its antioxidant rationale.[18,19] This makes NAC a reasonable adjunct for clinicians thinking upstream about oxidative burden.
Silymarin and fatty liver
For the patient with insulin resistance plus fatty liver, silymarin deserves consideration. Systematic reviews and meta-analyses suggest silymarin may improve liver biochemistry and some aspects of liver injury in NAFLD/MASLD, though it should be presented honestly as supportive rather than definitive.[20-22] In other words, it is not a substitute for weight loss, food quality, and metabolic correction—but it may be a useful piece of the strategy.
This is why a formula such as Mito-Detox III makes sense as part of a broader stacked protocol.*
OMEGA-3S: MEMBRANE HEALTH, TRIGLYCERIDES, AND METABOLIC FUNCTION
Cell membranes matter. Receptor function matters. Inflammation resolution matters. Omega-3 fatty acids—especially EPA and DHA—can be very helpful in the insulin-resistant patient, particularly when triglycerides are elevated or liver fat is part of the picture. Meta-analytic and scientific statement data support meaningful triglyceride reduction at doses above (roughly) 2 grams per day of marine omega-3s, with broader anti-inflammatory and membrane-related metabolic relevance.[23-25]
This is why I would strongly consider Biospec’s Super Omega Plus as part of the stack, especially at 3 to 4 softgels daily, providing roughly 1.8 to 2.4 g EPA/DHA. This is a clinically meaningful range for supporting healthy triglycerides, membrane function, and overall metabolic resilience.*[23,24]
LIFESTYLE STILL HAS TO LEAD
No supplement stack can outrun a poor food environment and sedentary physiology.
If clinicians want to move insulin resistance in the right direction, the foundational message still matters. In my clinical experience, many patients do not move the needle enough with a mild reduction in carbohydrates. More often, you must be far more aggressive. A lower-carbohydrate Mediterranean-style pattern is often a good starting point, but in patients with significant insulin resistance, abdominal obesity, elevated triglycerides, fatty liver, or rising fasting insulin, it may take reducing carbohydrate intake down to approximately 30 grams per day to begin seeing meaningful metabolic improvement. Clinically, this is typically when the waistline finally begins to respond, fasting insulin starts to drop, triglycerides improve, and patients begin moving in the right direction.
This does not mean every patient needs the same diet forever. But it does mean that in many insulin-resistant patients, dabbling around the edges is not enough. Remove ultra-processed foods. Remove sugar. Drive carbohydrate intake low enough to get results. Prioritize protein, non-starchy vegetables, healthy fats, better sleep, and regular movement. Patients do not need perfection. But they do need direction.
And many of them need to hear this plainly:
Your waistline is not merely reflecting calories. It is often reflecting hormonal and metabolic dysfunction.
BIOSPEC CLINICAL PERSPECTIVE*
In the right patient, stacking targeted nutritional support may help restore more normal physiology in several overlapping areas:
This is the lens I would encourage clinicians to use. Do not chase isolated numbers only. Address the terrain.
BIOSPEC NUTRITIONAL PROTOCOL FOR INSULIN RESISTANCE*
Clinician education / structure-function framework
Diet and dietary supplements are not designed to treat a disease, but rather to support the normal function that may lead to improved health outcomes. Within this framework, the following stacked protocol may help support healthy glucose metabolism, insulin sensitivity, hepatic function, redox balance, and normal cardiometabolic physiology in appropriate patients.*
1) FOUNDATION SUPPORT – GLUCOSE-IR*
A core formula built around:
Clinical rationale: Two capsules twice daily before meals - supports healthy insulin signaling, postprandial glucose handling, carbohydrate metabolism, and broader glycemic balance.*[7-13]
2) ADD MITO-DETOX III*
Key rationale ingredients:
Clinical rationale: Two capsules twice daily with or without food - supports mitochondrial function, antioxidant status, glutathione biology, fatty acid handling, and hepatic resilience; especially relevant when insulin resistance coexists with fatigue, oxidative stress, or mild to moderate fatty liver.*[14-22]
3) ADD SUPER OMEGA PLUS*
Clinical rationale: Three to four softgels daily with meals (providing 1.8 – 2.4 g EPA/DHA) supports healthy triglycerides, cell membrane integrity, receptor function, and a healthier inflammatory balance.*[23-25]
4) IF HYPERTENSION IS PRESENT, CONSIDER CARDIO-EASE BP*
Clinical rationale: One to two capsules twice daily can be considered as part of a broader plan to support healthy vascular tone and blood pressure already within normal range, especially in the insulin-resistant patient whose cardiometabolic burden extends beyond glucose alone.*
5) IF DYSLIPIDEMIA IS PRESENT, STACK CHOLESTEROL COMPLETE CAPS*
Clinical rationale: Insulin resistance is one of the leading drivers of dyslipidemia, especially elevated triglycerides, low HDL, and ApoB-containing particle burden in the wrong metabolic context.[5,6] In this patient, adding a lipid-support formula is often rational rather than optional.
6) CONSIDER FIBRO-EASE MULTI*
Clinical rationale: One to two tablets twice daily helps cover possible micronutrient insufficiencies that may undermine mitochondrial function, energy production, and normal metabolic physiology.*
7) IF VITAMIN D IS INSUFFICIENT, ADD BIO D/K PLUS
Clinical rationale: One to two liposomal capsules (depending on labs and clinical judgment) supports nutrient sufficiency and broader metabolic resilience when low vitamin D status is present.
8) ALWAYS PAIR WITH FOOD AND LIFESTYLE INTERVENTION
FINAL CLINICAL TAKEAWAY
If you want to know where chronic disease is heading, don’t just focus on glucose.
Look at the waistline.
Look at the triglycerides.
Look at the liver.
Look at insulin levels.
Insulin resistance is often sitting in plain sight long before overt disease is diagnosed. This is the bad news.
The good news is that insulin resistance is also one of the most modifiable processes in clinical practice when we identify it early and intervene intelligently.
†Biospec Nutritionals — Medical & Educational Disclaimer
This content is provided for educational and informational purposes only and is not intended to provide medical advice, diagnosis, or treatment. It is not a substitute for individualized guidance from a qualified healthcare professional. Always consult your physician or other qualified healthcare provider before starting, stopping, or changing any supplement, medication, diet, or exercise program.
*FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
[1] American Diabetes Association. Standards of Care in Diabetes—2026. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes.
[2] American Diabetes Association. Standards of Care in Diabetes—2025. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes.
[3] Chen J, et al. Association of visceral obesity indices with diabetic complications and cardiometabolic risk. 2024.
[4] Klein S, et al. Waist circumference and cardiometabolic risk: a consensus statement. Am J Clin Nutr. 2007.
[5] AASLD/AACE practice guidance on metabolic dysfunction-associated steatotic liver disease.
[6] Fan JG, et al. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease, 2024.
[7] Guo J, et al. The effect of berberine on metabolic profiles in type 2 diabetic patients: systematic review and meta-analysis of randomized controlled trials. 2021.
[8] Xie W, et al. Glucose-lowering effect of berberine on type 2 diabetes: systematic review and meta-analysis. 2022.
[9] Moridpour AH, et al. The effect of cinnamon supplementation on glycemic control in type 2 diabetes: meta-analysis of RCTs. 2024.
[10] Allen RW, et al. Cinnamon use in type 2 diabetes: updated systematic review and meta-analysis. 2013.
[11] Asbaghi O, et al. Effects of chromium supplementation on glycemic control in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials. 2020.
[12] Lown M, et al. Mulberry extract improves glucose tolerance and decreases insulin concentrations in normoglycemic adults. 2017.
[13] Shinkawa Y, et al. Randomized double-blind placebo-controlled crossover trial of mulberry leaf for postprandial hyperglycemia suppression. 2025.
[14] Rahimlou M, et al. Alpha-lipoic acid supplementation and glycemic/inflammatory biomarkers: meta-analysis. 2019.
[15] Mahmoudi-Nezhad M, et al. Updated systematic review and dose-response meta-analysis of alpha-lipoic acid and insulin resistance. 2021.
[16] Abolfathi M, et al. Effects of carnitine supplementation on clinical parameters in NAFLD: meta-analysis. 2020.
[17] Liu A, et al. Efficacy and safety of L-carnitine supplementation on NAFLD: systematic review and meta-analysis. 2023.
[18] Nikbaf-Shandiz M, et al. Systematic review and meta-analysis of NAC and liver function outcomes. 2023.
[19] Khoshbaten M, et al. N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease. 2010.
[20] Li S, et al. Administration of silymarin in NAFLD/NASH: systematic review. 2024.
[21] Kalopitas G, et al. Impact of silymarin in individuals with NAFLD: meta-analysis. 2021.
[22] Zhong S, et al. PRISMA meta-analysis of silymarin in NAFLD. 2017.
[23] Basirat A, et al. Marine-based omega-3 fatty acids and metabolic syndrome: systematic review/meta-analysis. 2025.
[24] AHA Scientific Statement. Omega-3 fatty acids for the management of hypertriglyceridemia. 2019.
[25] Sinha S, et al. The effect of omega-3 fatty acids on insulin resistance. 2023.